Haekyung Jeon-Slaughter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haekyung Jeon-Slaughter has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Bala Ramanan
VA North Texas Health Care System, Dallas, Texas, USA; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA
6 shared publicationsShirling Tsai
VA North Texas Health Care System, Dallas, Texas, USA; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA
6 shared publicationsXiaofei Chen
Oncology Biometrics, AstraZeneca, Gaithersburg, Maryland, USA
5 shared publicationsHang Nguyen
Veterans Affairs North Texas Health Care System, Dallas, TX, United States of America; Southern Methodist University, Dallas, TX, United States of America
4 shared publicationsRamin Ebrahimi
Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, California, USA; Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA
4 shared publicationsErum Z. Whyne
VA North Texas Health Care System, Dallas, Texas, USA
3 shared publications
Latest Publications
- 26 March 2026
- Published by Taylor & Francis in Journal of Social Distress and Homelessness
- p. 1-23
Veterans’ lived experiences with transitioning from prison: an evaluation of goals and barriers to success after incarceration
U.S. military veteran incarceration poses a significant public health dilemma. Recent data estimates that over 107,000 veterans are incarcerated in federal or state prisons (Maruschak et al., 2021)...
- 26 March 2026
- Published by Taylor & Francis in Journal of Social Distress and Homelessness
- p. 1-23
Veterans’ lived experiences with transitioning from prison: an evaluation of goals and barriers to success after incarceration
U.S. military veteran incarceration poses a significant public health dilemma. Recent data estimates that over 107,000 veterans are incarcerated in federal or state prisons (Maruschak et al., 2021)...
- Open Access
- 27 February 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (8) , 1765-1776
New 10-Year Atherosclerosis Cardiovascular Disease Risk Score for Asian and American Indian Women Service Members
- 27 February 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (8) , 1765-1776
Open AccessNew 10-Year Atherosclerosis Cardiovascular Disease Risk Score for Asian and American Indian Women Service Members
- Open Access
- 8 October 2025
- Published by Wiley in The Prostate
- Vol. 86 (2) , 227-235
Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core
Background: While male breast cancer incidence is rare, veteran status is found to be associated with increased risk, for incidence, a higher prevalence of male breast cancer patients was observed among male veteran prostate cancer survivors. This study leveraged the existing large‐scale Veterans Affairs (VA) Prostate Cancer Data Core and examined factors associated with increased risk of male breast cancer incidence in veterans with prior prostate cancer diagnoses. Methods: A retrospective cohort study of 1.3 million male veterans treated for prostate cancer at VA hospitals was conducted using the VA Prostate Cancer Data Core. Of these, 11,327 (0.86%) were newly diagnosed with male breast cancer on average 5.4 years post prostate cancer diagnosis. Results: Multivariate Cox and competing risk model results found that younger onset age of prostate cancer (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.97–0.98), metastasized prostate cancer (HR 2.03, 95% CI 1.90–2.17), being Non‐Hispanic (N‐H) Black (HR 1.10, 95% CI: 1.05–1.15), radiation (HR 1.06, 95% CI: 1.02–1.11) and androgen deprivation therapy (ADT; HR 1.24, 95% CI 1.17–1.32) were associated with significantly increased risk of male breast cancer diagnosis. Prolonged use of cardiovascular disease (CVD) medications, furosemide (HR 1.51, 95% CI 1.39–1.63), spironolactone (HR 1.36; 95% CI 1.15–1.61), and digoxin (HR 1.50, 95% CI: 1.29–1.72), significantly increased risk for male breast cancer incidence. Conclusions: Younger age onset of prostate cancer, metastasized prostate cancer, prolonged use of CVD medications, radiation, and ADT cancer treatment were factors significantly associated with increased risk of being diagnosed with male breast cancer among male veteran prostate cancer survivors. The study findings may shed insights in cardio‐oncology specific risk factors for male breast cancer among prostate cancer survivors.
- 8 October 2025
- Published by Wiley in The Prostate
- Vol. 86 (2) , 227-235
Open AccessFactors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core
Background: While male breast cancer incidence is rare, veteran status is found to be associated with increased risk, for incidence, a higher prevalence of male breast cancer patients was observed among male veteran prostate cancer survivors. This study leveraged the existing large‐scale Veterans Affairs (VA) Prostate Cancer Data Core and examined factors associated with increased risk of male breast cancer incidence in veterans with prior prostate cancer diagnoses. Methods: A retrospective cohort study of 1.3 million male veterans treated for prostate cancer at VA hospitals was conducted using the VA Prostate Cancer Data Core. Of these, 11,327 (0.86%) were newly diagnosed with male breast cancer on average 5.4 years post prostate cancer diagnosis. Results: Multivariate Cox and competing risk model results found that younger onset age of prostate cancer (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.97–0.98), metastasized prostate cancer (HR 2.03, 95% CI 1.90–2.17), being Non‐Hispanic (N‐H) Black (HR 1.10, 95% CI: 1.05–1.15), radiation (HR 1.06, 95% CI: 1.02–1.11) and androgen deprivation therapy (ADT; HR 1.24, 95% CI 1.17–1.32) were associated with significantly increased risk of male breast cancer diagnosis. Prolonged use of cardiovascular disease (CVD) medications, furosemide (HR 1.51, 95% CI 1.39–1.63), spironolactone (HR 1.36; 95% CI 1.15–1.61), and digoxin (HR 1.50, 95% CI: 1.29–1.72), significantly increased risk for male breast cancer incidence. Conclusions: Younger age onset of prostate cancer, metastasized prostate cancer, prolonged use of CVD medications, radiation, and ADT cancer treatment were factors significantly associated with increased risk of being diagnosed with male breast cancer among male veteran prostate cancer survivors. The study findings may shed insights in cardio‐oncology specific risk factors for male breast cancer among prostate cancer survivors.
- Open Access
- 12 August 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (9) , 102060
External Validation of the Veterans Affairs Women Cardiovascular Disease Risk Score to Nonveteran Women
- 12 August 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (9) , 102060
Open AccessExternal Validation of the Veterans Affairs Women Cardiovascular Disease Risk Score to Nonveteran Women
- Open Access
- 26 June 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (7) , 687
Correction: Chen et al. Sex Difference in Cigarette-Smoking Status and Its Association with Brain Volumes Using Large-Scale Community-Representative Data. Brain Sci. 2023, 13, 1164
- 26 June 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (7) , 687
Open AccessCorrection: Chen et al. Sex Difference in Cigarette-Smoking Status and Its Association with Brain Volumes Using Large-Scale Community-Representative Data. Brain Sci. 2023, 13, 1164
- Open Access
- 28 October 2024
- Published by Wiley in The Prostate
- Vol. 85 (2) , 148-155
Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real‐World Retrospective Study
Introduction: Prostate cancer is the most common cancer in men in the United States with low survival rates once metastasized. Abiraterone is approved for use in castrate‐sensitive and castrate‐resistant prostate cancer and is used extensively in the Veterans Affairs (VA) healthcare system. Spironolactone, a diuretic used to treat heart failure, edema, ascites, and hypertension, may increase androgen levels and reduce effectiveness of abiraterone when used concurrently to treat prostate cancer patients. While previous case studies support this, no large epidemiology studies have been conducted. The current study utilizes the large, VA prostate cancer data core and evaluates the effect of concomitant spironolactone on efficacy of abiraterone treatment in metastatic prostate cancer patients.Patients and Methods: The study selected 18,943 veterans with metastatic prostate cancer on abiraterone treatment. Of these, 581 patients (3.1%) were also on concomitant spironolactone. The concomitant treatment group, abiraterone + spironolactone, significantly differed from the abiraterone‐only group in body mass index, prevalence rates of heart failure and liver disease, and being previously treated with docetaxel. A 1:1 propensity score matching method was used to balance sample sizes and baseline traits between the two treatment groups, abiraterone versus abiraterone + spironolactone. Kaplan–Meier curves and Cox proportional hazard model were used to compare 5‐year overall survival and all‐cause mortality outcomes, respectively, between the two groups.Results: After propensity score matched, the abiraterone + spironolactone group was treated with abiraterone significantly longer than the abiraterone‐only group (mean ± standard deviation days 549.0 ± 552.3 vs. 435.5 ± 474.1; p = 0.0002) and had a higher 5‐year overall survival rate (44% vs. 37%; p = 0.0116). Veterans with metastatic prostate cancer treated with abiraterone + spironolactone also had a lower 5‐year all‐cause mortality compared to those only on abiraterone (hazard ratio 0.80, 95% confidence intervals 0.61–0.96; p = 0.012).Conclusion: This large VA observational study suggests that concomitant use of spironolactone does not compromise cancer control or survival of metastatic prostate cancer patients treated with abiraterone.
- 28 October 2024
- Published by Wiley in The Prostate
- Vol. 85 (2) , 148-155
Open AccessEffects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real‐World Retrospective Study
Introduction: Prostate cancer is the most common cancer in men in the United States with low survival rates once metastasized. Abiraterone is approved for use in castrate‐sensitive and castrate‐resistant prostate cancer and is used extensively in the Veterans Affairs (VA) healthcare system. Spironolactone, a diuretic used to treat heart failure, edema, ascites, and hypertension, may increase androgen levels and reduce effectiveness of abiraterone when used concurrently to treat prostate cancer patients. While previous case studies support this, no large epidemiology studies have been conducted. The current study utilizes the large, VA prostate cancer data core and evaluates the effect of concomitant spironolactone on efficacy of abiraterone treatment in metastatic prostate cancer patients.Patients and Methods: The study selected 18,943 veterans with metastatic prostate cancer on abiraterone treatment. Of these, 581 patients (3.1%) were also on concomitant spironolactone. The concomitant treatment group, abiraterone + spironolactone, significantly differed from the abiraterone‐only group in body mass index, prevalence rates of heart failure and liver disease, and being previously treated with docetaxel. A 1:1 propensity score matching method was used to balance sample sizes and baseline traits between the two treatment groups, abiraterone versus abiraterone + spironolactone. Kaplan–Meier curves and Cox proportional hazard model were used to compare 5‐year overall survival and all‐cause mortality outcomes, respectively, between the two groups.Results: After propensity score matched, the abiraterone + spironolactone group was treated with abiraterone significantly longer than the abiraterone‐only group (mean ± standard deviation days 549.0 ± 552.3 vs. 435.5 ± 474.1; p = 0.0002) and had a higher 5‐year overall survival rate (44% vs. 37%; p = 0.0116). Veterans with metastatic prostate cancer treated with abiraterone + spironolactone also had a lower 5‐year all‐cause mortality compared to those only on abiraterone (hazard ratio 0.80, 95% confidence intervals 0.61–0.96; p = 0.012).Conclusion: This large VA observational study suggests that concomitant use of spironolactone does not compromise cancer control or survival of metastatic prostate cancer patients treated with abiraterone.
- Open Access
- 23 February 2024
- Published by Springer Nature in npj Women's Health
- Vol. 2 (1) , 1-7
Ten-year atherosclerotic cardiovascular disease risk trajectories among women veteran cancer patients
Despite a higher risk of cardiovascular disease (CVD) events in women cancer survivors than their male counterparts, importance of female sex has been underestimated due to under-representation of women in clinical research and male dominant CVD risk models. This study examined ten-year Atherosclerosis Cardiovascular Disease (ASCVD) risk trajectories in women veterans diagnosed with the ten most common cancers—bladder, breast, colorectal, endometrial/uterine/cervix, leukemia, liver, lung and bronchium, Non-Hodgkin’s lymphoma, melanoma, and thyroid cancer—using United States (US) Veterans Affairs (VA) Electronic Health Records data. The study included 78,556 women veterans aged between 30 and 80 years from diverse backgrounds treated at VA hospitals with ≥2 complete outpatient visit records in the VA health care system between January 01, 2007 and December 31, 2017. A steep rise in ASCVD risk score trajectories post-cancer diagnosis was observed among women diagnosed with bladder, breast, liver, lung and thyroid cancer, melanoma, and Non-Hodgkin’s lymphoma, compared to pre-cancer diagnosis periods, as well as significantly elevated pre-cancer ASCVD risk among all patients with cancer, other than thyroid cancer, compared to the no cancer group (p < 0.0001). ASCVD risk monitoring is highly recommended to reduce adverse cardiovascular events for women diagnosed with cancer, survivors, and for women at risk of future cancer incidences.
- 23 February 2024
- Published by Springer Nature in npj Women's Health
- Vol. 2 (1) , 1-7
Open AccessTen-year atherosclerotic cardiovascular disease risk trajectories among women veteran cancer patients
Despite a higher risk of cardiovascular disease (CVD) events in women cancer survivors than their male counterparts, importance of female sex has been underestimated due to under-representation of women in clinical research and male dominant CVD risk models. This study examined ten-year Atherosclerosis Cardiovascular Disease (ASCVD) risk trajectories in women veterans diagnosed with the ten most common cancers—bladder, breast, colorectal, endometrial/uterine/cervix, leukemia, liver, lung and bronchium, Non-Hodgkin’s lymphoma, melanoma, and thyroid cancer—using United States (US) Veterans Affairs (VA) Electronic Health Records data. The study included 78,556 women veterans aged between 30 and 80 years from diverse backgrounds treated at VA hospitals with ≥2 complete outpatient visit records in the VA health care system between January 01, 2007 and December 31, 2017. A steep rise in ASCVD risk score trajectories post-cancer diagnosis was observed among women diagnosed with bladder, breast, liver, lung and thyroid cancer, melanoma, and Non-Hodgkin’s lymphoma, compared to pre-cancer diagnosis periods, as well as significantly elevated pre-cancer ASCVD risk among all patients with cancer, other than thyroid cancer, compared to the no cancer group (p < 0.0001). ASCVD risk monitoring is highly recommended to reduce adverse cardiovascular events for women diagnosed with cancer, survivors, and for women at risk of future cancer incidences.
- Open Access
- 4 August 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (8) , 1164
Sex Difference in Cigarette-Smoking Status and Its Association with Brain Volumes Using Large-Scale Community-Representative Data
Background: Cigarette smoking is believed to accelerate age-related neurodegeneration. Despite significant sex differences in both smoking behaviors and brain structures, the active literature is equivocal in parsing out a sex difference in smoking-associated brain structural changes. Objective: The current study examined subcortical and lateral ventricle gray matter (GM) volume differences among smokers, active, past, and never-smokers, stratified by sex. Methods: The current study data included 1959 Dallas Heart Study (DHS) participants with valid brain imaging data. Stratified by gender, multiple-group comparisons of three cigarette-smoking groups were conducted to test whether there is any cigarette-smoking group differences in GM volumes of the selected regions of interest (ROIs). Results: The largest subcortical GM volumetric loss and enlargement of the lateral ventricle were observed among past smokers for both females and males. However, these observed group differences in GM volumetric changes were statistically significant only among males after adjusting for age and intracranial volumes. Conclusions: The study findings suggest a sex difference in lifetime-smoking-associated GM volumetric changes, even after controlling for aging and intracranial volumes.
- 4 August 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (8) , 1164
Open AccessSex Difference in Cigarette-Smoking Status and Its Association with Brain Volumes Using Large-Scale Community-Representative Data
Background: Cigarette smoking is believed to accelerate age-related neurodegeneration. Despite significant sex differences in both smoking behaviors and brain structures, the active literature is equivocal in parsing out a sex difference in smoking-associated brain structural changes. Objective: The current study examined subcortical and lateral ventricle gray matter (GM) volume differences among smokers, active, past, and never-smokers, stratified by sex. Methods: The current study data included 1959 Dallas Heart Study (DHS) participants with valid brain imaging data. Stratified by gender, multiple-group comparisons of three cigarette-smoking groups were conducted to test whether there is any cigarette-smoking group differences in GM volumes of the selected regions of interest (ROIs). Results: The largest subcortical GM volumetric loss and enlargement of the lateral ventricle were observed among past smokers for both females and males. However, these observed group differences in GM volumetric changes were statistically significant only among males after adjusting for age and intracranial volumes. Conclusions: The study findings suggest a sex difference in lifetime-smoking-associated GM volumetric changes, even after controlling for aging and intracranial volumes.
- Open Access
- 17 July 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (14) , 6380
The Effects of Subjective Wellbeing and Self-Rated Health on Lifetime Risk of Cardiovascular Conditions in Women
Subjective wellbeing may predict future health conditions, and lower self-rated physical health (SRH) is associated with the presence of chronic conditions, such as cardiovascular disease (CVD). This study examines whether subjective wellbeing and SRH predict long-term CVD conditions for women using the Midlife in the United States study. The study cohort includes 1716 women participants who completed waves 1 (1995–1996), 2 (2004–2006), and 3 (2013–2014). Data on demographics, chronic conditions of diabetes and CVD, subjective wellbeing (life satisfaction, positive affect, and negative affect), and SRH were collected repeatedly at each wave. Multiple logistic regressions were conducted to test whether subjective wellbeing was associated with a lifetime CVD risk. Greater life satisfaction was significantly associated with a lower risk of CVD at 10 years (odds ratio (OR): 0.83; 95% confidence interval (CI): 0.74–0.95) and 19 years (OR: 0.83; 95% CI: 0.74–0.93), while positive and negative affects were not significantly associated. Additionally, better physical SRH significantly lowered odds of having cardiovascular conditions at both 10 years (OR: 0.79; 95% CI 0.68–0.92) and 19 years (OR 0.74; 95% CI: 0.64–0.86). Measures of life satisfaction and SRH can be used as additional CVD screening tools.
- 17 July 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (14) , 6380
Open AccessThe Effects of Subjective Wellbeing and Self-Rated Health on Lifetime Risk of Cardiovascular Conditions in Women
Subjective wellbeing may predict future health conditions, and lower self-rated physical health (SRH) is associated with the presence of chronic conditions, such as cardiovascular disease (CVD). This study examines whether subjective wellbeing and SRH predict long-term CVD conditions for women using the Midlife in the United States study. The study cohort includes 1716 women participants who completed waves 1 (1995–1996), 2 (2004–2006), and 3 (2013–2014). Data on demographics, chronic conditions of diabetes and CVD, subjective wellbeing (life satisfaction, positive affect, and negative affect), and SRH were collected repeatedly at each wave. Multiple logistic regressions were conducted to test whether subjective wellbeing was associated with a lifetime CVD risk. Greater life satisfaction was significantly associated with a lower risk of CVD at 10 years (odds ratio (OR): 0.83; 95% confidence interval (CI): 0.74–0.95) and 19 years (OR: 0.83; 95% CI: 0.74–0.93), while positive and negative affects were not significantly associated. Additionally, better physical SRH significantly lowered odds of having cardiovascular conditions at both 10 years (OR: 0.79; 95% CI 0.68–0.92) and 19 years (OR 0.74; 95% CI: 0.64–0.86). Measures of life satisfaction and SRH can be used as additional CVD screening tools.
- 22 July 2022
- Published by Elsevier in Thrombosis Research
- Vol. 217, 60-63
COVID-19 associated Venous Thromboembolism (VTE) burden in Black women: Findings of Veterans Affairs COVID-19 Shared Data
- 22 July 2022
- Published by Elsevier in Thrombosis Research
- Vol. 217, 60-63
COVID-19 associated Venous Thromboembolism (VTE) burden in Black women: Findings of Veterans Affairs COVID-19 Shared Data